Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for NYSE:BVF
143.00
+3.00 (2.14%)
Dec 18 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 139.53 - 143.50
52 week 106.00 - 153.10
Open 141.90
Vol / Avg. 0.00/2.19M
Mkt cap 47.11B
P/E 96.76
Div/yield     -
EPS 1.48
Shares 335.67M
Beta 0.84
Inst. own 59%
Feb 25, 2015
Q4 2014 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 8, 2015
Valeant Pharmaceuticals International Inc 2015 Financial Guidance Call - 8:00AM EST - Add to calendar
Oct 20, 2014
Q3 2014 Valeant Pharmaceuticals International Inc Earnings Release
Oct 20, 2014
Q3 2014 Valeant Pharmaceuticals International Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 13.44% -14.97%
Operating margin 33.26% -8.22%
EBITD margin - 51.28%
Return on average assets 4.03% -3.76%
Return on average equity 21.28% -19.60%
Employees 17,200 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. In June 2014, Akorn Inc sold its subsidiary, ECR Pharmaceuticals (ECR) to Valeant Pharmaceuticals International, Inc. In July 2014, the Company acquired PreCision Dermatology, Inc.

Officers and directors

J. Michael Michael Pearson Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Bhaskar Chaudhuri Ph.D. President
Age: 59
Bio & Compensation  - Reuters
Howard Bradley Schiller Chief Financial Officer, Executive Vice President, Director
Bio & Compensation  - Reuters
Peter J. Blott Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Elisa A. Karlson Executive Vice President, Chief Administrative Officer
Age: 53
Bio & Compensation  - Reuters
Robert Roswell Chai-Onn Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development
Age: 42
Bio & Compensation  - Reuters
Steve T. Min Executive Vice President, General Counsel, Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Ari Kellen Executive Vice President, Company Group Chairman
Bio & Compensation  - Reuters
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Bio & Compensation  - Reuters
Martin N Mercer Executive VP, International
Bio & Compensation  - Reuters